Search Results - "Min, Y.J."

6570 POSTER Update of AMC 0201 Study – a Randomized Phase III Trial Comparing Mitomycin-C Plus Short-term Doxifluridine (Mf) Versus Mitomycin-C Plus Long-term Doxifluridine Plus Cisplatin (MFP) After Curative Resection of Advanced Gastric Cancer (NCT00296335) by Min, Y.J, Kang, Y.K, Ryoo, B.Y, Zang, D.Y, Kim, G.Y, Yang, D.H, Jang, S.J, Yook, J.H, Oh, S.T, Kim, B.S

Get full text

1859P Identifying the competence of the medical workers and the method of managing severe side effects in the management of chemotherapy by Kim, H., Koh, S-J., Ock, M., Cho, J., Cheon, J., Min, Y.J., Im, H-S., Seo, S., Kim, J.

Get full text

6577 POSTER Prospective phase II trial of a combination of gemcitabine, cisplatin and UFT as first-line treatment in patients with advanced, unresectable, non-small cell lung carcinoma by Shin, S.J, Min, Y.J, Baek, J.H, Kim, H, Ann, J.J, Jegal, Y.J, Park, C.Y, Cha, H.J, Kwon, W.J, Park, J.H

Get full text

Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea by Cho, E.K., Kang, J.H., Han, J.-Y., Lee, J.S., Kim, D.-W., Kim, S.-W., Min, Y.J., Lee, K.H., Kim, J.-H., Park, K.

Get full text

1275PEFFICACY OF EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS) IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER EXCEPT BOTH EXON 19 DELETION AND EXON 21 L858R: A RETROSPECTIVE ANALYSIS IN KOREA by Baek, J.H., Min, Y.J., Cho, E.K., Cho, B., Kim, J., Sun, J., Ahn, M., Park, K.

“…Abstract Aim: NSCLC can be defined by various molecular criteria, especially by the status of EGFR mutation. Two major EGFR mutations are exon 19 deletions…”
Get full text

Efficacy of Egfr Tyrosine Kinase Inhibitors (Egfr Tkis) in Patients with Egfr-Mutated Non-Small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L858R: a Retrospective Analysis in Korea by Baek, J.H., Min, Y.J., Cho, E.K., Cho, B., Kim, J., Sun, J., Ahn, M., Park, K.

Get full text

669PTHE ROLE OF ADJUVANT CHEMOTHERAPY FOR ELDERLY PATIENTS WITH GASTRIC CANCER AFTER A GASTRECTOMY IN KOREA by Jo, J., Baek, J.H., Koh, S., Min, Y.J., Cho, H.R., Kim, G.Y.

“…Abstract Aim: Adjuvant chemotherapy is recommended for gastric cancer after a gastrectomy with D2 dissection. However, its survival benefit in elderly patients…”
Get full text

The Role of Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer After a Gastrectomy in Korea by Jo, J., Baek, J.H., Koh, S., Min, Y.J., Cho, H.R., Kim, G.Y.

Get full text

Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial by Goss, G.D., Cobo, M., Lu, S., Syrigos, K., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Isla, D., Morabito, A., Min, Y.J., Ardizzoni, A., Cseh, A., Bender, S., Felip, E.

Get full text

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung by Goss, G., Lee, K.H., Felip, E., Cobo, M., Syrigos, K., Goker, E., Georgioulias, V., Guclu, S.Z., Isla, D., Min, Y.J., Morabito, A., Dupuis, N., Chand, V.K., Solca, F., Krämer, N., Gibson, N., Ehrnrooth, E., Soria, J.C.

Get full text

Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study by Lim, S.M., Cho, B.C., Kim, H.R., Lee, J.-S., Lee, K.H., Lee, Y.-G., Min, Y.J., Cho, E.K., Lee, S.-S., Kim, B.-S., Choi, M.Y., Shim, H.S., Chung, J.H., Choi, Y.L., Lee, M.J., Ahn, M.-J.

Get full text

OP09 Association of patient sex with chemotherapy-related adverse events: A multicenter retrospective cohort study by Choi, S., Seo, S., Lee, J.H., Kim, J.H., Koh, S-J., Ahn, Y., Kim, T.W., Hong, Y.S., Kim, S.Y., Kim, J.E., Kim, S-W., Lee, D.H., Lee, J., Choi, C-M., Yoon, S., Kim, H.J., Suh, K.J., Kim, S.H., Kim, Y.J., Min, Y.J., Baek, J.H., Park, S.R., Kim, J.H.

Get full text

425PD Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC by Lee, J.-S., Park, K., Han, J.-Y., Lee, K.H., Kim, J.-H., Cho, E.K., Cho, J.Y., Min, Y.J., Kim, J.-S., Kim, H.-G., Kim, B.-S., Jung, J., Kim, D.-W.

Get full text

1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8) by Goss, G., Felip, E., Cobo, M., Lu, S., Syrigos, K.N., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Isla, D., Morabito, A., Guclu, S.Z., Min, Y.J., Ardizzoni, A., Gadgeel, S., Love, J., Chand, V., Soria, J-C.

“…Abstract Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts with SCC of the head/neck and lung. Here, we report…”
Get full text

A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8) by Goss, G., Felip, E., Cobo, M., Lu, S., Syrigos, K.N., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Isla, D., Morabito, A., Guclu, S.Z., Min, Y.J., Ardizzoni, A., Gadgeel, S., Love, J., Chand, V., Soria, J-C.

Get full text

Visfatin stimulates proliferation of MCF-7 human breast cancer cells by Kim, Jae Geun, Kim, Eun Ok, Jeong, Bo Ra, Min, Young Joo, Park, Jeong Woo, Kim, Eun Sook, Namgoong, Il Seong, Kim, Young Il, Lee, Byung Ju

“…Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin…”
Get more information

Induction Chemotherapy in Patients with Acute Myeloid Leukemia by Lee, J.-H., Joo, Y.-D., Kim, H., Bae, S.H., Kim, M.K., Zang, D.Y., Lee, J.-L., Lee, G.W., Park, J.-H., Kim, D.-Y., Lee, W.-S., Ryoo, H.M., Hyun, M.S., Kim, H.J., Min, Y.J., Lee, K.-H.

Get full text

Delimitation of Russula Subgenus Amoenulla in korea Using Three Molecular Markers by Park, M.S., Seoul National University, Seoul, Republic of korea, Fong, J.J., Seoul National University, Seoul, Republic of korea, Lee, H., Seoul National University, Seoul, Republic of korea, Jung, P.E., Seoul National University, Seoul, Republic of korea, Min, Y.J., Seoul National University, Seoul, Republic of korea, Seok, S.J., RDA, Suwon, Republic of Korea, Lim, Y.W., Seoul National University, Seoul, Republic of korea

“…Distinguishing individual Russula species has been difficult due to extensive phenotypic plasticity and obscure morphological and anatomical discontinuties…”
Get full text

Nucleotide sequences of a Korean isolate of apple stem grooving virus associated with black necrotic leaf spot disease on pear (Pyrus pyrifolia) by Shim, Hyekyung, Min, Yeonju, Hong, Sungyoul, Kwon, Moonsik, Kim, Daehyun, Kim, Hyunran, Choi, Yongmoon, Lee, Sukchan, Yang, Jaemyung

“…Pear black necrotic leaf spot (PBNLS) is a disease of pears caused by capillovirus-like particles, which can be observed under the electron microscope. The…”
Get more information

The Intention To Treat Analysis of the Different Post Remission Therapy Modalities in AML Patients with the “Intermediate Risk Group (IPG)” Based on Cytogenetics by Mun, Yeung-Chul, Lee, S.M., Park, S.H., Cho, E.K., Lee, J.H., Jo, D.Y., Kim, I.H., Yoon, S.S., Park, S.Y., Bang, S.M., Min, Y.J., Seo, J.J., Lee, M.H., Kim, C.S., Joo, Y.D., Chung, S.Y., Oh, D.Y., Zang, D.Y., Lee, K.H., Hyun, M.S., Song, H.S., Kim, H.S., Kwon, H.C., Kim, H.J., Park, Y.H., Ahn, M.J., Ahn, J.S., Park, K.T., Bae, S.H., Ryoo, H.M., Yoon, H.J., Kim, B.S., Ghim, Thad, Seong, Chu-Myong

“…The results of cytogenetics are one of the most important prognostic factors in the prognosis of AML. Three different post remission therapies were given with…”
Get full text